Company: ACBM
Filing Date: 2025-07-24
Form Type: 10-K
Source: 0001640334-25-001300
Chunk: 511

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-24
Form: 10-K
Item: Item 9A
Chunk 511
---
 part of these financial statements.

 F-5Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Cash Flows

  Year ended   December 31,   2024  2023        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(42,297) $(8,807,573)Adjustments to reconcile net loss to net cash used in operating activities:        Imputed interest - related parties  4,339   3,206 Amortization of deferred stock compensation  -   8,060,983 Provision for doubtful accounts  -   480,000 Provision for purchase deposit write off  -   12,000 Changes in operating assets and liabilities:        Accounts receivable  -   158,500 Security deposit  -   (370)Prepaid expenses  1,250   (65)Accounts payable and accrued expenses  16   77,873 Net cash used in operating activities  (36,692)  (15,446)         CASH FLOWS FROM FINANCING ACTIVITIES        Advances from related parties  36,792   9,970 Net cash provided by financing activities  36,792   9,970          Net change in cash  100   (5,476)Cash at beginning of period  376   5,852 Cash at end of period $476  $376          SUPPLEMENTAL CASH FLOW INFORMATION:        Cash paid for income taxes $-  $- Cash paid for interest $-  $-          NON CASH INVESTING AND FINANCING ACTIVITIES        Increase in the right-of-use asset and lease liability $-  $52,233 

The accompanying notes are an integral part of these financial statements.

 F-6Table of Contents

ACRO BIOMEDICAL CO., LTD.

Notes to the Financial Statements

NOTE 1 -ORGANIZATION AND DESCRIPTION OF BUSINESS Acro Biomedical Co., Ltd. (the “Company”) is a Nevada corporation incorporated on September 24, 2014 under the name Killer Waves Hawaii, Inc. On January 30, 2017, the Company’s corporate name was changed to Acro Biomedical